Synchron is pioneering advancements in neurotechnology through its innovative brain-computer interface (BCI) designed to empower individuals with limited hand mobility. The BCI enables users to control digital devices using their thoughts, facilitating everyday tasks such as texting, scheduling appointments, and making purchases. This technology employs a minimally invasive endovascular procedure, akin to stent placement, which eliminates the need for open brain surgery. The core components of Synchron's system include the Stentrode Electrode array, which detects motor signals within blood vessels, and the Integrated Receiver Transmitter (IRT) that communicates these signals to a personal device, such as a smartphone or tablet.

The potential of Synchron's BCI extends to restoring autonomy for patients with severe motor impairments, such as those with tetraplegia. By utilizing implantable micro-neuroprosthetic devices, the technology aims to continuously transmit motor intent, thereby allowing users to interact with their digital environments more freely. The system's design emphasizes safety and efficacy, as it is currently classified as an investigational device under U.S. law, highlighting the ongoing research and development efforts to refine its capabilities and ensure patient well-being.

Australia

Synchron is a Brain Computer Interface company based in Campbell, California and Melbourne, Australia. We are developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability.

Synchron

Company Details